Business Context and Reporting Period
Company: GRI Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2024
Reporting Period: Quarter ended September 30, 2024
Context: The filing announces the issuance of a press release containing financial results and a business update for the third quarter of 2024.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data are disclosed within the text of this specific filing. The document serves solely to notify the market of the release of the Q3 2024 results.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a business update alongside the financial results, though the content of this update is not included in the filing text.
Legal Disclaimer: The information in this report and the attached press release is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, nor is it incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2024) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "business update" mentioned in Item 2.02, as they are not detailed in the 8-K text.
- Confirm the Company's status as an Emerging Growth Company (indicated as yes in the filing).
- Check the Nasdaq Capital Market listing status for Common Stock (Symbol: GRI).